Skip to main content

Peer Review reports

From: Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy

Original Submission
24 Sep 2021 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
17 Feb 2022 Reviewed Reviewer Report
22 Feb 2022 Reviewed Reviewer Report
12 Apr 2022 Author responded Author comments - Gianluca Furneri
Resubmission - Version 3
12 Apr 2022 Submitted Manuscript version 3
16 Apr 2022 Reviewed Reviewer Report
19 Apr 2022 Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
20 Apr 2022 Editorially accepted
29 Apr 2022 Article published 10.1186/s12913-022-07972-w

You can find further information about peer review here.

Back to article page